Glaucoma Updates Post-COVID: The pandemic hasn't slowed progress in new care options

Authors :: Karpecki, Paul M.
Source :: Review of Optometry. July 15, 2020, Vol. 157 Issue 7, p14, 1 p.
Publication Year :: 2020
Abstract: Despite the COVID-19 lockdown, the FDA has continued to approve new therapeutics, many of which will impact how we manage glaucoma. The approval of Durysta (bimatoprost implant, Allergan), for example, [...]

Subjects :: Ophthalmic agents -- Licensing, certification and accreditation -- Innovations -- Usage
Telemedicine -- Usage -- Methods -- Social aspects
Eye surgery -- Methods -- Social aspects -- Usage
Ophthalmoscopes -- Innovations -- Usage
COVID-19 -- Social aspects
Glaucoma -- Drug therapy -- Diagnosis
Health
Durysta (Medication) -- Licensing, certification and accreditation -- Usage

Tools